Skip to main content
SpringerLink
Log in

Disorders of Calcium Metabolism

  • Chapter
Therapy of Renal Diseases and Related Disorders

  • 182 Accesses

Abstract

The adult human body contains 1.3 kg of calcium of which 99% is contained in bones and teeth, 1% in cells of soft tissue, and 0.15% in the extracellular fluid (1). The bone calcium is in the form of hydroxyapatite crystals, and the exchange of calcium between bone and extracellular fluid occurs by two mechanisms: bone turnover, which is concerned with replacement and remodeling of bone and involves coupled osteoclastic resorption and osteblastic deposition, and homeostatic equilibration, which is concerned with the regulation of the plasma calcium level (2, 3). The normal total plasma calcium concentration is 4.5–5.1 mEq/1 (9–10.2mg/dl). Of the total calcium 40–43% is bound to plasma protens (mainly albumin), 5–10% is combined with anions such as citrate and phosphate to form nonionized complexes, and the remaining 40–50% is free ionized calcium. Only this last fraction is physiologically active. In addition, a small amount of calcium is also bound to serum globulins.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Parfitt AM, Kleerekoper M: The divalent ion homeostasis system. Physiology and metabolism of calcium, phosphorus, magnesium and bone. In: MH Maxwell, CR Kleeman, eds, Clinical Disorders of Fluid & Electrolyte Metabolism. McGraw-Hill, New York, p269, 1980.

    Google Scholar 

  2. Parfitt AM: The actions of parathyroid hormone on bone. 1. Metabolism 25:809, 1976.

    PubMed  CAS  Google Scholar 

  3. Parfitt AM: The actions of parathyroid hormone on bone. II. Metabolism 25:904, 1976.

    Google Scholar 

  4. Loken HF, Havell RJ, Gordon GS, Wittinton SL: Ultra-centrifugal analysis of protein-bound and free calcium in human serum. J Biol Chem 235:3654, 1960.

    PubMed  CAS  Google Scholar 

  5. Moore EW: Ionized calcium in normal serum, ultrafiltrates and whole blood determined by ion exchange electrodes. J Clin Invest 49:318, 1970.

    PubMed  CAS  Google Scholar 

  6. Pedersen KO: The effect of bicarbonate pCO2 and pH on serum calcium fractions. Scand J Clin Lab Invest 27:145, 1970.

    Google Scholar 

  7. Walser M, Robinson BH, Duckett JW: The hypercalcemia of adrenal insufficiency. J Clin Invest 42:456, 1963.

    PubMed  CAS  Google Scholar 

  8. Jaffe JP, Mosher DF: Calcium binding by a myeloma protein. Am J Med 67:343, 1979.

    PubMed  CAS  Google Scholar 

  9. Lim P, Jacob E, Chio LF, Pwee HS: Serum ionized calcium in nephrotic syndrome. Q J Med 179–421, 1973.

    Google Scholar 

  10. Berry EM, Gupta MM, Turner SJ, Burns RR: Variations in plasma calcium with changes in plasma specfic gravity, total protein and alburmin. Br Med J 4:640, 1973.

    PubMed  CAS  Google Scholar 

  11. Husdan H, Rapoport A, Lock S: Influence of posture on the serum concentration of calcium. Metabolism 22:787, 1973.

    Google Scholar 

  12. Raisz LG: Physiologic and pharmacologic regulation of bone resoprtion. N Engl J Med 282:909, 1973.

    Google Scholar 

  13. Slatopolsky E, Martin K, Morrissey J, Hruska K: Parathyroid hormone secretion metabolism and biologic actions. Semin Nephrol 1:319, 1981.

    CAS  Google Scholar 

  14. Kleeman CR, Bernstein D, Rockney R, Dowling JT, Maxwell M H: Studies on the renal clearance of diffusible calcium and the role of parathyroid glands on its regulation. Yale J Biol Med 34:1, 1961.

    PubMed  CAS  Google Scholar 

  15. Widrow SH, Levinsky NG: The effect of parathyroid extract on renal tubular calcium reabsorption in the dog. J Clin Invest 41:2151, 1982.

    Google Scholar 

  16. Massry SG, Coburn JW, Chapman LW, Kleeman CR: Role of serum calcium, parathyroid hormone and NaCl infusion, on renal calcium and Na clearances. Am J Physiol 214:1403, 1968.

    PubMed  CAS  Google Scholar 

  17. Shareghi GR, Stoner LC: Calcium transport across segments of the rabbit distal nephron in vitro. Am J Physiol 235:F367, 1978.

    PubMed  CAS  Google Scholar 

  18. Greger R, Lang F, Oberleithner H: Distal site of calcium reabsorption into the rat nephron. Pflügers Arch 374:153, 1978.

    PubMed  CAS  Google Scholar 

  19. Favus MJ. Transport of calcium by intestinal mucosa. Semin Nephrol 1:306, 1981.

    CAS  Google Scholar 

  20. Myrtle JF, Norman AW: Vitamin D: A cholecalciferol metabolite highly active in promoting intestinal calcium transport. Science 171:79, 1971.

    PubMed  CAS  Google Scholar 

  21. Walling MW: Intestinal calcium and phosphate transport. Differential responses to Vitamin D3 metabolites. Am J Physiol 233:E488, 1977.

    PubMed  CAS  Google Scholar 

  22. Lee DBN, Brautbar N, Massry SG Renal production and biologic actions of vitamin D metabolites. Semin Nephrol 1:335, 1981.

    CAS  Google Scholar 

  23. Hirsch PE, Munson PL: Thyrocalcitonin. Physiol Rev 49:548, 1969.

    PubMed  CAS  Google Scholar 

  24. Copp DH: Endocrine regulation of calcium metabolism. Ann Review Physiol 32:61, 1970.

    CAS  Google Scholar 

  25. Nicolayson R: The absorption of calcium as a function of body saturation with calcium. Acta Physiol Scand 6:201, 1943.

    Google Scholar 

  26. Boyle IT, Gray RW, DeLuca HF: Regulation by calcium of in vivo synthesis of 1,25 hydroxycholecalciferol and 21,25 hydroxycholecalciferol. Proc Natl Acad Sci USA 68:2131, 1971.

    PubMed  CAS  Google Scholar 

  27. DeCristofaro JB, Tsang, RC: Calcium (review). Emerg Med Clin North Am 4(2):207.21, 1986.

    PubMed  Google Scholar 

  28. Parfitt AM: Equilibrium and disequilibrium hypercalcemia. New light on and old concept. Metab Bone Dis Related 1:279, 1979.

    Google Scholar 

  29. Stewart AF, Horst R, Deftos LJ, Cadman EC, Lang R, Broadus AE: Biochemical evaluation of patients with cancer associated with hypercalcemia. Evidence for humoral and non-humoral groups. N Engl J Med 303:1377, 1980.

    PubMed  CAS  Google Scholar 

  30. Mundy RG: Pathogenesis of hypercalcemia of malignancy (review). Clin Endocrinol (Oxford) 23:705, 1985.

    CAS  Google Scholar 

  31. Mundy RG, Raisz LG, Cooper RA, Schechter GP, Salmon SE: Evidence for the secretion of an osteoclast stimulating factor in myeloma. N Engl J Med 291:1041, 1974.

    PubMed  CAS  Google Scholar 

  32. Ralston SH, Fogelman I, Gardiner MD, Boyle IT: Relative contribution of humoral and metastatic factors to the pathogenesis of hypercalcemia in malignancy. Br Med J 288:1405, 1984.

    CAS  Google Scholar 

  33. Breslau NA, McGuire JL, Zerwekh JE, Frenkl EP, Pak CYC: Hypercalcemia associated with increased serum calcitriol levels in 3 patients with lymphoma. Ann Int Med 100:1, 1984.

    PubMed  CAS  Google Scholar 

  34. Mosley JM, Kubota M, Diefenbach-Jagger H, Wettenhall REH, Kemp BE, Suva LJ, Rodda CP, Ebeling PR, Hudson PJ, Zajac JD, Martin TJ: Parathyroid hormone-related protein purified from a human lung cancer cell line. Bone Mineral Research Congress (ASBMR), Abs No. 391, Indianapolis, 1987.

    Google Scholar 

  35. Stewart AF, Wu T, Goumas D, Burtis WJ: Amino-terminal sequence of a human HHM-associated adenylate cyclase-stimulating protein contains PTH-like and PTH-unlike domains. Bone Mineral Research Congress (ASBMR), Abs No. 392, Indianapolis, 1987.

    Google Scholar 

  36. Katz A, Kaplan L, Massry SG, Heller R, Plotkin D, Knight I: Primary hyperparathyroidism in patients with breast carcinoma. Arch Surg 101:582, 1970.

    PubMed  CAS  Google Scholar 

  37. Kaplan L, Katz AD, Ben Isaac C, Massry SG: Malignant neoplasms and parathyroid adenomas. Cancer 28:401, 1971.

    PubMed  CAS  Google Scholar 

  38. Far HW, Fahey TJ Jr, Nash AG, Farr CM: Primary hyperparathyroidism in cancer. Am J Surg 126:539, 1973.

    Google Scholar 

  39. Samaan NA, Hickey RC, Hill CS Jr, Medellin H, Gates R B: Parathyroid tumors. Preoperative localization and association with other tumors. Cancer 33:933, 1974.

    PubMed  CAS  Google Scholar 

  40. Vichayanrat A, Abramides A, Gardner B, Wallach S, Carter A C: Primary hyperparathyroidism in breast cancer. Am J Med. 61:136, 1976.

    PubMed  CAS  Google Scholar 

  41. Singer FR, Sharp CF, Rude R K: Pathogenesis of hypercalcemic malignancy. Miner electrolyte Metab 2:161, 1979.

    Google Scholar 

  42. Robinson RG, Kerwin DM, Tsou E: Parathyroid adenoma with coexistent sarcoid granulomas. Hypercalcemic patient. Arch Intern Med 140: 1980.

    Google Scholar 

  43. Case records of the Massachusetts General Hospital: Weekly clinicopathological exercises. Case 50–1981. N Engl J Med 305:1457, 1981.

    Google Scholar 

  44. Farr HW, Fahey TJ Jr, Nash AG, Farr CM: Primary hyperparathyroidism and cancer. Am J Surg 126:539, 1973.

    PubMed  CAS  Google Scholar 

  45. Heath DA: Hypercalcemia and malignancy. Ann Clin Biochem 13:555, 1976.

    PubMed  CAS  Google Scholar 

  46. Rao DS, Frame B, Block MA, Parfitt AM: Primary hyperparathyroidism. A cause of hypercalciuria and renal stones in patients with medullary sponge kidney. JAMA 237:1353, 1977.

    PubMed  CAS  Google Scholar 

  47. Gremillion DH, Kee JW, Mcintosh DA: Hyperparathyroidism and medullary sponge kidney. JAMA 237:436, 1977.

    Google Scholar 

  48. Vaishnava H, Rizvi SNA: Primary hyperparathyroidism associated with nutritional osteomalacia. Am J Med 45:640, 1976.

    Google Scholar 

  49. Keynes WM, Caird FI: Hypocalcemic primary hyperparathyroidism. Br Med J 1:208, 1970.

    PubMed  CAS  Google Scholar 

  50. Dent CE, Jones PE, Mullan DP: Masked primary (or tertiary) hyperparathryroidism. Lancet 1:1161, 1975.

    PubMed  CAS  Google Scholar 

  51. Woodhouse NJY, Doyle FH, Joplin GF: Vitamin D deficiency and primary hyperparathyroidism. Lancet 2:282, 1971.

    Google Scholar 

  52. Levi J, Massry SG, Coburn JW, Llach F, Kleeman CR: Hypocalcemia in magnesium depleted dogs: Evidence for reduced responsiveness to parathyroid hormone and relative failure of parathyroid gland function. Metabolism 23:323, 1974.

    PubMed  CAS  Google Scholar 

  53. Cope D, Culver PJ, Mixter CG, Nardi GL: Pancreatitis — a diagnosis clue to hyperparathyroidism. Ann Surg 145:857, 1957.

    PubMed  CAS  Google Scholar 

  54. Lever EG: Primary hyperparathyroidism masked by hypothyroidism. Am J Med 74:144, 1983.

    PubMed  CAS  Google Scholar 

  55. Muldowney FP, Freaney R, McMullin JP, Towers RP, Spillane A, O’Connor P, O’Donohoe P, and Moloney M: Serum ionized calcium and parathyroid hormone in renal stone disease. Q J Med 45:75, 1976.

    PubMed  CAS  Google Scholar 

  56. Pak CYC, Nicar MJ, Peterson R, Zerwekh JE, Snyder W: A lack of unique pathophysiologic background for nephrolithiasis of primary hyperparathyroidism. J Clin Endocrinol Metab 53:536, 1981.

    PubMed  CAS  Google Scholar 

  57. Broadus AF, Horst RL, Lang R, Littledike ET, Rassmussen H: Circulating 1,25 dihydroxyvitamin D in primary hyperparathyroidism. N Engl J Med 302:421, 1980.

    PubMed  CAS  Google Scholar 

  58. Edis AJ, Evans TC Jr: High-resolution, real-time ultrasonography in the preoperative location of parathyroid tumors. Pilot study. N Engl J Med 301:532, 1979.

    PubMed  CAS  Google Scholar 

  59. Brewer WH, Walsh JW, Newsome HH Jr: Impact of sonography on surgery for primary hyperparathyroidism. Am J Surg 145:270, 1983.

    PubMed  CAS  Google Scholar 

  60. Ferlin G, Borsato N, Camerani M, Conte N, Zotti D: New perspectives in localizing enlarged parathyroids by technetium-thallium subtraction scan. N Nucl Med 24:438, 1983.

    CAS  Google Scholar 

  61. Etiology and treatment of primary hyperparathyroidism (editorial). Lancet 1:367, 1983.

    Google Scholar 

  62. Brennan MF, Doppman JL, Marx SJ, Spiegel AM, Brown EM, Aurbach GD: Reoperative parathyroid surgery for persistent hyperparathyroidism. Surgery 83:669, 1983.

    Google Scholar 

  63. Doppman JL, Lawrence E, Mallette MD, Marx SJ, Monchik JM, Broadus A, Spiegel AM, Beazley R, Aurbach GD: The localization of abnormal mediastinal parathyroid glands. Radiology 115:31, 1975.

    PubMed  CAS  Google Scholar 

  64. Wolverson MK, Sundaram M, Eddelston B, Prendergast J: Diagnosis of parathyroid adenoma by computed tomography for localization of parathyroid adenomas. J Comput Assist Tomogr 5:818, 1981.

    PubMed  CAS  Google Scholar 

  65. Whitley NO, Bohlman M, Connor TB, McCrea ES, Mason GR, Whitley J E: Computed tomography for localization of parathyroid adenomas. J Comput Assist Tomogr 5:812, 1981.

    PubMed  CAS  Google Scholar 

  66. Foley TP Jr, Harrison HC, Arnaud CD, Harrison HE: Familial benign hypercalcemia. J Pediatrics 81:1060, 1972.

    Google Scholar 

  67. Marx SJ, Spiegel AM, Brown EM, Koehler JO, Gardner DG, Brennan MF, Aurbach GD: Divalent cation metabolism. Familial hypocalciuric hypercalcemia versus typical primary hyperparathyroidism. Am J Med 65:235, 1978.

    PubMed  CAS  Google Scholar 

  68. Marx SJ, Spiegel AM, Brown EM, Windeck R, Gardner DG, Downs RW Jr, Attie M, Aurbach GD: Circulating parathyroid hormone activity: Familial hypocalciuric hypercalcemia versus typical primary hyperparathyroidism. J Clin Endo Metab 47:1190, 1978.

    CAS  Google Scholar 

  69. Davies M, Klimiuk PS, Adams PH, Lumb GA, Large DM, Anderson DC: Familial hypocalciuric hypercalcemia and acute pancreatitis. Br Med J 282:1023, 1981.

    CAS  Google Scholar 

  70. Stote RM, Smith LH, Wilson DM, Dube WJ, Goldsmith RS, Arnaud CD: Hydrochlorothiazide effects on serum calcium and immunoreactive parathyroid hormone concentrations. Studies in normal subjects. Ann Intern Med 77:587, 1972.

    PubMed  CAS  Google Scholar 

  71. Hossain M: Vitamin D intoxication during treatment for hypoparathyroidism. Lancet 1:1149, 1970.

    PubMed  CAS  Google Scholar 

  72. Hughes MR, Baylink D, Jones PG, Haussler MR: Radioligand receptor assay for 25-hydroxyvitamin D2/D3, and 1-alpha 25-dihydroxyvitamin D2/D3. Application to hyper-vitaminosis D. J Clin Invest 58:61, 1976.

    PubMed  CAS  Google Scholar 

  73. Counts SJ, Baylink DJ, Shen FH, Sherrard DJ, Hickman RO: Vitamin D intoxication in an anephric child. Ann Int Med 82:196, 1975.

    PubMed  CAS  Google Scholar 

  74. Papapoulos SE, Clemens TL, Fraher LJ, Lewin IG, Sandler LM, O’Riordan JLH: 1,25 dihydroxycholecalciferol in the pathogenesis of the hypercalcemia of sarcoidosis. Lancet 1:627, 1979.

    PubMed  CAS  Google Scholar 

  75. Bell NH, Stern PH, Pantzer E, Sinha TK, DeLuca HF: Evidence that increased circulating 1-alpha 25-dihydroxyvitamin D is the probable cause for abnormal calcium metabolism in sarcoidosis. J Clin Invest 64:L218, 1979.

    Google Scholar 

  76. Barbour GL, Coburn JW, Slatopolsky E, Norman AW, Horst RL: Hypercalcemia in an anephric patient with sarcoidosis: Evidence for extrarenal generation of 1,25-dihydroxyvitamin D. N Engl J Med 305:440, 1981.

    PubMed  CAS  Google Scholar 

  77. Adams JS, Sharma OP, Singer FR: Metabolism of 25-hydroxyvitamin D3 by alveolar macrophages in sarcoidosis. Clin Res 31:499A, 1983.

    Google Scholar 

  78. Baxter JD, Bondy PK: Hypercalcemia of thyrotoxicosis. Ann Intern Med 65:429, 1966.

    PubMed  CAS  Google Scholar 

  79. Burman KD, Monchik JM, Earll JM, Wartofsky L: Ionized and total serum calcium and parathyroid hormone in hyperthyroidism. Ann Intern Med 84:668, 1976.

    PubMed  CAS  Google Scholar 

  80. Mosekilde J, Christensen MS: Decreased parathyroid function in hyperthyroidism: Interrelationships between serum parathyroid hormone, calcium-phosphorus metabolism and thyroid function. Acta Endocrinology 84:566, 1977.

    CAS  Google Scholar 

  81. Fritzel D, Malleson A, Marks V: Plasma levels of ionized calcium and magnesium in thyroid disease. Lancet 1:1360, 1977.

    Google Scholar 

  82. Krane SM, Brownell GL, Stanbury JB, Corrigon H: The effect of thyroid disease on calcium metabolism in man. J Clin Invest 35:874, 1956.

    PubMed  CAS  Google Scholar 

  83. Adams PH, Jowsey J, Kelly PJ, Riggs BL, Kinney VR, Jones JD: The effects of hyperthyroidism on bone and mineral metabolism in man. Q J Med 36:1, 1967.

    CAS  Google Scholar 

  84. Mundy GR, Shapiro JL, Bandelin JC, Canalis EM, Raisz IG: Direct stimulation of bone resorption by thyroid hormones. J Clin Invst 58:529, 1975.

    Google Scholar 

  85. Rude RK, Oldham SB, Singer FR, Nicoloff JT: Treatment of thyrotoxic hypercalcemia with propranolol. N Engl J Med 294:431, 1976.

    PubMed  CAS  Google Scholar 

  86. Finlayson JF, Casey JH: Hypercalcemia and multiple pheochromocytomas. Ann Intern Med 82:810, 1975.

    PubMed  CAS  Google Scholar 

  87. Heath H, Edis AJ: Pheochromocytoma associated with hypercalcemia and ectopic secretion of calcitonin. Ann Intern Med 91;208, 1979.

    PubMed  Google Scholar 

  88. Jorgensen H: Hypercalcemia in adrenocortical insufficiency. Acta Med Scand 193:175, 1973.

    PubMed  CAS  Google Scholar 

  89. Tuttle SG, Figueroa WG: Hypercalciuria associated with reduction in corticoid therapy after prolonged administration of prednisone and after bilateral adrenalectomy for Cushing’s syndrome. J Clin Invest 37:937, 1958.

    Google Scholar 

  90. Nadarajah A, Hartog M, Redfern B, Thalassinos N, Wright AD, Joplin GE, Fraser TR: Calcium metabolism in acromegaly. Br Med J 4:797, 1968.

    PubMed  CAS  Google Scholar 

  91. Sjoberg HE: Retention of oral 45calcium in acromegaly. Horm Metab Res 1:136, 1969.

    PubMed  CAS  Google Scholar 

  92. Riggs BL, Randall RV, Wahner HW, Jowsey J, Kelly PM, Singh M: The nature of the metabolic bone disorder in acromegaly. J Clin Endocrinol Metab 34:911, 1972.

    PubMed  CAS  Google Scholar 

  93. Eskildsen PC, Lund B, Sorensen OH, Lund BI, Bishop JE, Norman AW: Acromegaly and vitamin D metabolism: Effect of bromocriptine treatment. J Clin Endocrinol metab 41:484, 1979.

    Google Scholar 

  94. Hirose S, Kobayashi K, Kajikawa K, Sawabu N, Takeuchi J: A case of watery diarrhea, hypokalemia and hypercalcemia associated with nonulcerogenic islet cell tumor of the pancreas. Am J Gastroenterology 64:382, 1975.

    CAS  Google Scholar 

  95. Frame B, Jackson CE, Reynolds WA, Umphrey JE: Hypercalcemia an skeletal effects in chronic hypervitaminosis A. Ann Int Med 80:44, 1974.

    PubMed  CAS  Google Scholar 

  96. Chertow BS, Williams GA, Norris RM, Baker GR, Hargis GK: Vitamin A stimulation of parathyroid hormone: Interactions with calcium, hydrocortisone, and vitamin E in bovine parathyroid tissues and effects of vitamin A in man. Eur J Invest 7:307, 1977.

    CAS  Google Scholar 

  97. Broadus AE, Mahaffey JE, Bartter FC, Neer RM: Nephrogenous cyclic adenosine monophosphate as a parathyroid function test. J Clin Invest 60:771, 1977.

    PubMed  CAS  Google Scholar 

  98. Broadus AE, Horst RL, Lang R, Travis, Littledike ET, Rasmussen H: The importance of circulating 1,25 dihydroxy vitamin D, and renal stone formation in primary hyperparathyroidism. N Eng J Med 302:421, 1980.

    CAS  Google Scholar 

  99. Adami S, Milroy EJG, O’Riordan JLH: Primary hyperparathyroidism. In: BEC Nordin, ed, Metabolic Bone and Stone disease. Churchill Livingstone, New York, p 112, 1984.

    Google Scholar 

  100. Broadus AE, Deftos LJ, Bartter FC: Effects of the intravenous administration of calcium on nephrogenous cyclic AMP. Use a parathyroid suppression test. J Clin Endocrinol Metab 46:477, 1978.

    PubMed  CAS  Google Scholar 

  101. Broadus AF, Horst RL, Littledike ET, Mahaffey JE, Rasmussen H: Primary hyperparathyroidism with intermittent hypercalcemia: Serial observations and simple diagnosis by means of an oral calcium tolerance test. Clin Endocrinol 12:225, 1980.

    CAS  Google Scholar 

  102. Watson L, Moxham J, Fraser P: Hydrocortisone suppression test and discriminant analysis in different diagnosis of hypercalcemia. Lancet 1:1320, 1980.

    PubMed  CAS  Google Scholar 

  103. Suki WN, Yium JJ, Von Minden M, Saller-Hebert C, Ecknoyan G, Martinez-Maldonado M: Acute treatment of hypercalcemia with furosemide. N Engl J Med 283:836, 1970.

    PubMed  CAS  Google Scholar 

  104. Elliott TG, McKenzie WH: Treatment of hypercalcemia. Drug Intell Clin Pharm 17:12, 1983.

    PubMed  CAS  Google Scholar 

  105. Brickman AS, Massry SG: Changes in serum and urinary calcium during treatment with hydrochlorothiazide. J Clin Invest 51:945, 1972.

    PubMed  CAS  Google Scholar 

  106. Parfitt AM: The interaction of thiazide diuretics with parathyroid hormone and vitamin D — studies in patients with hypoparathyroidism. J Clin Invest 51:1879, 1972.

    PubMed  CAS  Google Scholar 

  107. Goldsmith RS, Ingbar SH: Inorganic phosphate treatment of hypercalcemia of diverse etiologies. N Engl J Med 274:1, 1966.

    PubMed  CAS  Google Scholar 

  108. Herbert LA, Lemann J Jr, Petersen JR, Lennon EJ: Studies of the mechanism by which phosphate infusion lowers serum calcium concentration. J Clin Invest 45:1886, 1966.

    CAS  Google Scholar 

  109. Massry SG, Mueller E, Silverman AG, Kleeman CR: Inorganic phosphate treatment with hypercalcemia. Arch Intern Med 121:307, 1968.

    PubMed  CAS  Google Scholar 

  110. Carrol E, Pechet M: Stimulation of bone formation by inorganic phosphate and inhibition of bone resorption by thyrocalcitonin. J Clin Invest 46:1043, 1967.

    Google Scholar 

  111. Breuer RI, Le Bauer J: Caution in the use of phosphates in the treatment of severe hypercalcemia. J Clin Endocrinol 27:695, 1967.

    CAS  Google Scholar 

  112. Alijouni K, Rosenfeld PS: Treatment of hypercalcemia. Drug Ther 4:103, 1974.

    Google Scholar 

  113. Lee DBN, Zawada ET, Kleeman CR: The pathophysiology and clinical aspects of hypercalcemic disorders. Western J Med 129:278, 1978.

    CAS  Google Scholar 

  114. Yendt ER: Disorders of calcium, phosphorus, and magnesium metabolism. In: Maxwell MH, Kleeman CR, eds, Clinical Disorders of Fluid and Electrolyte Metabolism. McGraw-Hill, New York p 416, 1972.

    Google Scholar 

  115. Massry SG, Mueller E, Silverman AG, Kleeman CR: Inorganic phosphate treatment for hypercalcemia. Arch Intern Med 121:307, 1968.

    PubMed  CAS  Google Scholar 

  116. Coburn JW, Brickman AS, Massry SG: Medical treatment in primary and secondary hyperparathyroidism. Semin Drug Treatment 2:117, 1972.

    CAS  Google Scholar 

  117. Brautbar N, Luboshitzky R: Combined calcitonin and oral phosphate treatment for hypercalcemia in multiple myeloma. Arch Intern Med 137:914, 1977.

    PubMed  CAS  Google Scholar 

  118. Fleisch H, Felix R: Diphosphonates. Calif Tissue Int 27:91, 1979.

    CAS  Google Scholar 

  119. Shane E, Baquiran DC, Bilezikian J P: Effects of dichloromethylene diphosphonate on serum and urinary calcium in primary hyperparathyroidism. Ann Intern Med 95:23, 1981.

    PubMed  CAS  Google Scholar 

  120. Breukelen FJM, Bijvoet OLM, Van Oosterom AT: Inhibition of osteolytic bone lesions by (3-amino-l-hydroxypro-pyliden)-1, l-biphosphonate (A.P.D) Lancet 1:803, 1979.

    PubMed  Google Scholar 

  121. Siris ES, Sherman WH, Baquiran DC, Schlatter JP, Osserman EF, Canfield RE: Effects of dichloromethylene diphosphonate on skeletal mobilization of calcium in multiple myeloma. N Eng J Med 302:310, 1980.

    CAS  Google Scholar 

  122. Jacobs TP, Siris ES, Bilezikian JP, Baquiran DC, Shane E, Canfield RE: Hypercalcemia of malignancy: Treatment with intravenous dichloromethylene diphosphonate. Ann Intern Med 94:312, 1981.

    PubMed  CAS  Google Scholar 

  123. Chapuy MC, Meunier PJ, Alexandre CM, Vignon EP: Effects of disodium dichlormethylene diphosphonate on hypercalcemia produced by bone metatases. J Clin Invest 65:1243, 1980.

    PubMed  CAS  Google Scholar 

  124. Canfield R, Rosner W, Shinner J, et al.: Diphosphonate therapy of Paget’s disease of bone. J Clin Endocrinol Metab 44:96, 1977.

    PubMed  CAS  Google Scholar 

  125. Frijlink WB, TeVelde J, Bijvoet OLM, Heynen G: Treatment of Paget’s disease with (3-amino-l-hyroxypropylidene)-1, l-biphosphonate (A.P.D.) Lancet 1:799, 1979.

    PubMed  CAS  Google Scholar 

  126. Jaeger P, Williams J, Clemens LT, Hayslett PJ: Evidence that calcitonin stimulates 1,25-dihydroxy production and intestinal absorption of calcium in vivo. J Clin Invest 78:456, 1986.

    PubMed  CAS  Google Scholar 

  127. Silva OL, Becker KL: Salmon calcitonin in the treatment of hypercalcemia. Arch Intern Med 132:337, 1973.

    PubMed  CAS  Google Scholar 

  128. Habener JF, Singer FR, Deftos LJ, Potts JT: Immunological stability of calcitonin in plasma. Endocrinology 90:952, 1972.

    PubMed  CAS  Google Scholar 

  129. Singer FR, Aldred JP, Neer RM, Krane SM, Potts JT: An evaluation of antibodies and clinical resistance to salmon calcitonin. J Clin Invest 51:2331, 1972.

    PubMed  CAS  Google Scholar 

  130. Neer RM, Habener JF, Peacock N, Murray T: Escape from calcitonin (CT) during therapy of hypercalcemia. Clin Res 18:676, 1970.

    Google Scholar 

  131. Dube WJ, Goldsmith RS, Arnaud SB: Hyperparathyroidism secondary to long term therapy of Paget’s disease in bone with calcitonin. In: RV Talmag, PL Munson, eds, Calcium, Parathyroid Hormone and the Calcitonins. Excerptal Medical, Amsterdam, p 113, 1972.

    Google Scholar 

  132. Au WYW: Calcitonin treatment of hypercalcemia due to parathyroid carcinoma — synergistic effect of prednisone on long-term treatment of hypercalcemia. Arch Int Med 135: 1594, 1975.

    CAS  Google Scholar 

  133. Caro JF, Besarab A, Glennon JA: Symptomatic hypocalcemia following combined calcitonin and mithramycin therapy for hypercalcemia due to malignancy. Cancer Treat Rep 62:1561, 1978.

    PubMed  CAS  Google Scholar 

  134. Deftos LJ, Potts JT: Parathyroid hormone, thyrocalcitonin, vitamin D, bone and mineral metabolism. In: PL Bondy, ed, Duncan’s Disease of Metabolism. WB Saunders, Philadelphia, p 1225, 1974.

    Google Scholar 

  135. Reilly MJ, Kepler JA, Poor DM, Lande NI, Rolf BI, Douglas PM (eds): Am Hosp Form Serv 2:68, 1980.

    Google Scholar 

  136. Jee WSS, Roberts WE, Park HZ: Interrelated effects of glucocorticoid and parathyroid hormone upon bone remodelling. In: RV Talmage, PL Munson, eds, Calcium Parathryoid Hormone and the Calcitonins. Excerpta Medica, Amsterdam, p 430, 1972.

    Google Scholar 

  137. Collins EJ, Garett E, Johnston RL: Effect of adrenal steroids on radiocalcium metabolism in dogs. Metabolism 11:716, 1962.

    PubMed  CAS  Google Scholar 

  138. Loak H: The action of corticosteroid on the renal reabsorption of calcium. Acta Endocrinol 34:60, 1960.

    Google Scholar 

  139. Tashian AH, Voelkel EF, McDonough J: Hydrocortisone inhibits prostaglandin production by mouse fibrosarcoma cells. Nature 258:739, 1975.

    Google Scholar 

  140. Mundy GR, Rick ME, Turcotte R, Kowalski MA: Pathogenesis of hypercalcemia in lymphosarcoma cell leukemia: Role of an osteoclast activating factor-like substance and a mechanism of action for glucocorticoid therapy. Am I Med 5:600, 1978.

    Google Scholar 

  141. Potts JT: Disorders of the parathyroid gland. In: KJ Isselbacher, RD Adams, E Braunwald, RG Petersdorf, JD Wilson, eds, Harrison’s Principles of Internal Medicine. McGraw-Hill, p 1838, 1980.

    Google Scholar 

  142. Kennedy BJ: New York, Metabolic and toxic effects of mithramycin during tumor therapy. Am I Med 49:494, 1970.

    CAS  Google Scholar 

  143. Singer FR, Neer RM, Murray JM, Keutmann HT, Deftos LJ, Potts JT: Mithramycin treatment of intractable hypercalcemia due to parathryoid carcinoma. N Engl I Med 283:634, 1970.

    CAS  Google Scholar 

  144. Elias EG, Reyn G, Mittelman A: Control of hypercalcemia with mithramycin. Ann Surg 175:431, 1972.

    Google Scholar 

  145. Smith IE, Powles TJ: Mithramycin for hypercalcemia associated with myeloma and other malignancies. Br Med I 1:268, 1975.

    CAS  Google Scholar 

  146. Parsons V, Baum M: Effect of mithramycin on calcium and hydroxyproline metabolism in patients with malignant disease. Br Med J 1:474, 1967.

    PubMed  CAS  Google Scholar 

  147. Brereton HD, Halushk PV, Alexander RW, Mason DM, Keiwer HE, DeVita VT Jr: Indomethacin-responsive hypercalceia in a patient with renal-cell adenocarcinoma. NEngJ Med 291:83, 1974.

    CAS  Google Scholar 

  148. Robertson RP, Baylink DJ, Marini JJ, Adkison W: Elevated prostaglandins and suppressed parathyroid hormone assodated with hypercalcemia and renal cell carcinoma. J Clin Endocrinol Metab 41:164, 1975.

    PubMed  CAS  Google Scholar 

  149. Brenner DE, Harvey HA, Lipton A, Demers L: A study of prostaglandin E2, parathormone and response to indomethacin in patients with hypercalcemia of malignancy. Cancer 44:556, 1982.

    Google Scholar 

  150. Atkins D, Ibbotson KJ, Hillier K, Hunt NH, Hammonds JC, Martin TJ: Secretion of prostaglandins as bone resorbing agents by renal cortical carcinoma in culture. Br J Cancer 36:601, 1971.

    Google Scholar 

  151. Prescott LF: Anti-inflammatory analgesics and drugs used in rheumatoid arthritis and gout. In: MNG Dukes, ed, Meyler’s Side Effects of Drugs. American Elsevier, New York, pp 217, 1975.

    Google Scholar 

  152. Nolph KD, Stolt M, Maher JF: Calcium free peritoneal dialysis treatment of vitamin D intoxication. Arch Int Med 128:809, 1971.

    CAS  Google Scholar 

  153. Stolz ML, Nolph KD, Maher JF: Factors affecting calcium removal with calcium-free peritoneal dialysis. J Lab Clin Med 78:389, 1971.

    Google Scholar 

  154. Scholz D, Purnell D: Asymptomatic primary hyperparathyroidism: A 10-year prospective study. Mayo Clin Proc 56:473, 1981.

    PubMed  CAS  Google Scholar 

  155. Posen S, Clifton-Bligh P, Reeve TS, Wagstaffe C, Wilkinson M: Is parathyroidectomy of benefit in primary hyperparathyroidism? In: B Frame, JT Potts, eds, Clinical Disorders of Bone and Mineral Metabolism. Excerpta Medica, Amsterdam, p 154, 1983.

    Google Scholar 

  156. Neer R: Natural history of untreated hyperparathyroidism. Presented at Symposium on Clinical Disorders of Bone and Mineral Metabolism. May 1983.

    Google Scholar 

  157. Sherwood JK, Ackroyd FW, Garcia M: Effect of Cimetidine on circulating parathyroid hormone in primary hyperparathyroidism. Lancet 1:616, 1980.

    PubMed  CAS  Google Scholar 

  158. Caro JF, Castro JH, Glennon JA: Effect of long-term propranolol administration on parathyroid hormone and calcium concentration in primary hyperparathyroidism. Ann Int Med 91:740, 1979.

    PubMed  CAS  Google Scholar 

  159. Rude RK, Oldham SB, Singer FR, Nicoloff JT: Treatment of thyrotoxic hypercalcemia with propranolol. N Eng J Med 294:431, 1976.

    CAS  Google Scholar 

  160. Sigurdsson G, Woodhouse NJY, Taylor S, Joplin GF: Stilboestrol diphosphonate in hypercalcemia due to parathryoid carcinoma. Br Med J 1:27, 1973.

    PubMed  CAS  Google Scholar 

  161. Mundy GR, Wilkinson R, Heath DA: A comparative study of available medical therapy for hypercalcemia malignancy. Am J Med 74:421, 1983.

    PubMed  CAS  Google Scholar 

  162. Van Holten-Verzamdvoort A, Harinck HIJ, Hermans J, Cleton RJ, Bijvoet OLM: Supportive bisphosphonate treatment reduces morbidity from bone lesions in breast cancer (abstract). ASBMR, Bone Mineral Research Congress, Abs No. 390, Indianapolis, 1987.

    Google Scholar 

  163. Glover D, Riley L, Carmichael K, et al.: Hypocalcemia and inhibition of parathyroid hormone secretion after administration of WR-2721 (a radioprotective and chemoprotective agent). N Engl J Med 309:1137, 1983.

    PubMed  CAS  Google Scholar 

  164. Wolf J, Attie M, Fallar M, Goldfarb S: Studies of the hypocalcemic action of WR-2721. Clin Res 32:412, 1984.

    Google Scholar 

  165. Glover JD, Shaw L, Glick J, Slatopolsky E, Weiler C, Attie M, Goldfarb S: Treatment of hypercalcemia in parathyroid cancer with WR2721, S-2-(3-aminopropylamine) ethyl-phosphorothoric acid. Ann Int Med 103:55, 1985.

    PubMed  CAS  Google Scholar 

  166. Weiss J, Wolf J, Slatopolsky E, Fallar M, Attie M, Goldfarb S: Sustained hypocalcemia, inhibition of PTH secretion and correction of Vitamin D induced hypercalcemia with chronic administration of WR-2721 (abstract). Kidney Int 27:129(S), 1985.

    Google Scholar 

  167. Hunt BJ, Yendt ER: The response of hypercalcemia in sarcoidosis to chloroquine. Ann Int Med 59:554, 1963.

    PubMed  CAS  Google Scholar 

  168. O’Leary JT, Jones G, Yip A, Lohnes D, Cohanim M, Yendt E: The effects of chloroquine on serum 1,25-dihydroxy vitamin D and calcium metabolism in sarcoidosis. N Engl J Med 315:12, 1986.

    Google Scholar 

  169. Glass RA, Eil CH: Ketoconazole-induced reduction in serum 1,25-dihydroxy vitamin D. J Clin Endocrinol Metabolism 63:766, 1986.

    CAS  Google Scholar 

  170. Henry HL: Effect of ketoconazole and myconazole on 25-hydroxy D3 metabolism by cultured chick kidney cells. J Steroid Biochem 23:91, 1985.

    Google Scholar 

  171. Mishoulam HJ, Lad TE, Khan A, Kukla LJ, Abrahamson EC, McGuire WP, Kukreja SC: Effect of cisplatinum on hypercalcemia of malignancy. Clin Res 31:778a, 1983.

    Google Scholar 

  172. Kukla LJ, Abrahamson EC, Shevrin DH, Lad TE, Mcguire WP, Kukreja SC: Cisplatinum as treatment for humoral hypercalcemia of malignancy in an athymic mouse model. Clin Res 31:739A, 1983.

    Google Scholar 

  173. Walsh FB, Murray RG: Ocular manifestations of disturbances in calcium metabolism. Am J Ophth 36:1657, 1953.

    PubMed  CAS  Google Scholar 

  174. Barr DP, MacBride CM, Sanders TE: Tetany with increased intracranial pressure and papilledema. Results from treatment with hydrotachysterol. Trans Assoc Am Phys 53:227, 1938.

    Google Scholar 

  175. Ireland AW, Hornbrook JW, Neale FC, Posen S: The crystalline lens in chronic surgical hypoparathyroidism. Arch Int Med 122:408, 1969.

    Google Scholar 

  176. Camp JD: Symmetrical calcification of the cerebral basal ganglia, its roentgeneologic significance in the diagnosis of parathyroid insufficiency. Radiology 49:568, 1947.

    PubMed  CAS  Google Scholar 

  177. Levine P: Intracranial calcification associated with hypoparathyroidism. Bull NY Acad Med 38:632, 1962.

    Google Scholar 

  178. Chopra D, Janson P, Sawin CT: Insensitivity to digoxin associated with hypocalcemia. N Eng J Med 296:917, 1977.

    CAS  Google Scholar 

  179. Eipe J, Johnson SA, Kiamko RT, Bronksy D: Hypoparathyroidism following 131I therapy for hyperthyroidism. Arch Intern Med 121:270, 1968.

    PubMed  CAS  Google Scholar 

  180. Sagel J, Epstein S, Kalk J, Von Mieghen W: Radioactive iodine therapy for thyrotoxicosis at Groote Schuur Hospital over a 6 year period. Postgrad Med J 48:308, 1972.

    PubMed  CAS  Google Scholar 

  181. Robertson GM, Moore EW, Switz DM, Sizemore GW, Estep HL: Inadequate parathyroid response in acute pancreatitis. N Engl J Med 194:512, 1976.

    Google Scholar 

  182. Haldiman B, Goldstein DA, Akam M, Massry SG: Renal function and blood levels of divalent ions in acute pancreatitis. A prospective study in 99 patients. Miner Electolyte Metab 3:190, 1980.

    Google Scholar 

  183. Horwitz CA, Myers LWP, Foote FW: Secondary malignant tumors of the parathyroid glands. Report of 2 cases with associated hypoparathyroidism. Am J Med 52:797, 1972.

    PubMed  CAS  Google Scholar 

  184. Brezis M, Shalev O, Leibel B, Berenheim J, Ben Ishay D: Phosphorus retention and hypoparathyroidism associated with transfusion and iron overload in thalassemia. Miner Electrolyte Metab 4:57, 1980.

    Google Scholar 

  185. Drake TG, Albright F, Bauer W, Castleman B: Chronic idiopathic hypoparathyroidism. Report of 6 cases with autopsy findings. Ann Intern Med 12:1751, 1939.

    CAS  Google Scholar 

  186. Spinner MW, Blizzard RM, Childs B: Clinical and genetic heterogeneity in idiopathic Addison’s disease and hypoparathyroidism. J Clin Endocrinol Metab 28:795, 1968.

    PubMed  CAS  Google Scholar 

  187. Wilson PW, Buckley CE, Eisenbarth GS: Disordered immune function in patients with polyglandular failure. J Clin Endocrinol Metab 52:284, 1981.

    PubMed  CAS  Google Scholar 

  188. Nusynowitz ML, Frame B, Kolb FO: The spectrum of the hypoparathyroid states. A classification based on physiologic principles. Medicine (Baltimore) 55:105, 1976.

    CAS  Google Scholar 

  189. Klahr S, Slatopolsky E: Urinary phosphate and cyclic AMP in pseudohypoparathyroidism. In: SG Massry, E Ritz, A Rapado, eds, Homeostasis of Phosphate and Other Minerals. Plenum, New York, p 173, 1977.

    Google Scholar 

  190. Chase LR, Melson GL, Aurbach GD: Pseudohypoparathyroidism: Defective excretion of 3′5′-AMP in response to parathyroid hormone. J Clin Invest 48:1832, 1969.

    PubMed  CAS  Google Scholar 

  191. Farfel Z, Brickman AS, Kaslow HR, Brothers V, Bourne H: Defect of receptor cyclase coupling protein in pseudo-hypoparathryoidism. N Eng J Med 303:237, 1980.

    CAS  Google Scholar 

  192. Bourne HR, Kaslow HR, Brickman AS, Farfel Z: Fibroblast defect in pseudohypoparathyroidism Type I. Reduced activity of receptor cyclase coupling protein. J Clin Endocrinol Metab 53:636, 1981.

    PubMed  CAS  Google Scholar 

  193. Drezner M, Neelon FA, Lebovitz HE: Pseudohypoparathyroidism Type II. A possible defect in the reception of cyclic AMP signal. N Eng J Med 289:1056, 1973.

    CAS  Google Scholar 

  194. Rodriguez HJ, Villareal H, Klahr S, Slatopolsky E: Pseudohypoparathyroidism Type II. Restoration of normal renal responsiveness to parathyroid hormone by calcium administration. J Clin Endocrinol Metab 39:693, 1974.

    PubMed  CAS  Google Scholar 

  195. Daneman D, Kooh SW, Fraser D: Hypoparathyroidism in childhood. Clin Endocrinol Metab 11:211, 1982.

    PubMed  CAS  Google Scholar 

  196. Kolb FO, Steinbach HL: Pseudohypoparathyroidism with secondary hyperparathyroidism and osteitis fibrosa. J Clin Endocrinol 22:59, 1962.

    CAS  Google Scholar 

  197. Drezner MK, Neelon FA, Haussier M, McPherson HT, Lebovitz HE: 1,25-dihydroxycholecalciferol deficiency: The probable cause of hypocalcemia and metabolic bone disease in pseudo hypoparathyroidism. J Clin Endocrinol Metab 42:621, 1976.

    PubMed  CAS  Google Scholar 

  198. Pitkin RM: Calcium metabolism in pregnancy. A review. Am J Obstet Gynecol 121:724, 1975.

    PubMed  CAS  Google Scholar 

  199. Tsang RC, Light IJ, Sutherland JM, Kleinman LI: Possible pathogenetic factors in neonatal hypocalcemia of prematurity. J Pediatr 82:423, 1973.

    PubMed  CAS  Google Scholar 

  200. Tsang RC, Chen I-W, Friedman MA, Chen I: Neonatal parathyroid function: Role of gestational age and postnatal age. J Pediatr 83:728, 1973.

    PubMed  CAS  Google Scholar 

  201. Barltrop D: Neonatal hypocalcemia. Postgrad J 51 (Suppl 3): 7, 1975.

    Google Scholar 

  202. Rao DS, Parfitt AM, Kleerekoper M, Pumo BS, Mathews M, Frame B: Dissociation of cAMP and Phosphaturic response to PTH in human vitamin D deficiency. An acquired disorder simulating pseudohypoparathyroidism. Presented at VII Int. Conference on Calcium Regulating Hormones, Kobe, Japan, 1983.

    Google Scholar 

  203. Medalle K, Waterhouse C: A magnesium deficient patient presenting with hypocalcemia and hypophosphatemia. Ann Intern Med 79:76, 1973.

    PubMed  CAS  Google Scholar 

  204. Porter RH, Cox BA, Heaney D, Hostetter TH, Stinebaugh BJ, Suki W: Treatment of hypoparathyroid patients with chlorthalidone. N Eng J Med 298:578, 1978.

    Google Scholar 

  205. Peterson P, Gray P, Tolmn KG: Calcium balance in drug-induced osteomalacia: Response to vitamin D. Clin Pharm Ther 19:63, 1976.

    CAS  Google Scholar 

  206. Purnell DC, Scholtz DA, Smith LH, Sizemore GW, Black BM, Goldsmith RS, Arnaud CDP: Treatment of primary hyperparathyroidism. Am J Med 56:800, 1974.

    PubMed  CAS  Google Scholar 

  207. Parfitt AM: Adult hypoparathyroidism. Treatment with calcifediol. Arch Int Med 138:874, 1978.

    Google Scholar 

  208. Nagant De Deuxchaisnes C: Hyperparathyroidism. In: LV Avioli, SM Krane, eds, Metabolic Bone Disease, Vol 2. Academic Press, New York, 1978.

    Google Scholar 

  209. Bilezikian JP: Parathyroid hormone related peptide in sickness and in health. N Engl J Med 322:1151–1153, 1990.

    PubMed  CAS  Google Scholar 

  210. Budayr AA, Nissenson RA, Kline RF, et al.: Increased serum levels of a parathyroid hormone-like peptide in malignancy associated with hypercalcemia. Ann Intern Med 111:807–812, 1989.

    PubMed  CAS  Google Scholar 

  211. Henderson JE, Shustic C, Kramer R, et al.: Circulating concentrations of parathyroid hormone-like peptide in malignancy and hyperparathyroidism. J Bone Min Res 5:105–113, 1990.

    CAS  Google Scholar 

  212. Burtis WJ, Brady BS, Orloff JJ, et al.: Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer. N Engl J Med 322:1106–1112, 1990.

    PubMed  CAS  Google Scholar 

  213. Lindall AW, Elting J, Ells J, Rouse BA: Estimation of biologically activate intact parathyroid hormone in normal and hyperparathryoid sera by sequential N-terminal immunoextraction and mid region radioimmunoassay. J Clin Endocrinol Metab 57:1007, 1983.

    PubMed  CAS  Google Scholar 

  214. Nussbaum SR, Zahradink RJ, Lavinge JR, et al.: Highly sensitive two site immunoradiometric assay of parathyrin and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 8:1364–1367, 1987.

    Google Scholar 

  215. Blind, E, Schmidt-Gayk H, Scharia S, et al.: Two-site assay of intact parathyroid hormone in the investigation of primary hyperparathyroidism and other disorders of calcium metabolism compared with a midregion assay. J Clin Endocrinol Metab 67:353–360, 1988.

    PubMed  CAS  Google Scholar 

  216. Patron P, Gardin J-P, Paillard M: Renal mass and reserve of vitamin D: determinants in primary hyperparathyroidism. Kidney Int 31:1174–1180, 1987.

    PubMed  CAS  Google Scholar 

  217. Potts JT Jr: Management of asymptomatic hyperparathyroidism. J Clin Endocrinol Metab 70:1489–1493, 1980.

    Google Scholar 

  218. Ralston SH, Gallacher SJ, Patel U, et al.: Cancer associated hypercalcemia, morbidity and mortality. Clinical experience in 126 patients. Ann Intern Med 112:499–504, 1990.

    PubMed  CAS  Google Scholar 

  219. Harinck HIJ, Bijvoet OLM, Plantingh AST, et al.: Role of bone and kidney in tumour induce hypercalcemia and its treatment with bisphosphonate and sodium chloride. Am J Med 82:1133–1142, 1987.

    PubMed  CAS  Google Scholar 

  220. Ralston SH, Dryburgh FJ, Cowan RA, et al.: Comparision of aminohydroxypropylidene diphosphonate, mithramycin and corticosteroids/calcitonin in treatment of cancer associated hypercalcemia. Lancet 2:907–910, 1985.

    PubMed  CAS  Google Scholar 

  221. Etridronate disodium: A new therapy for hypercalcemia of malignancy. Am J Med 82 (2A):1–78, 1987.

    Google Scholar 

  222. Warrell RP Jr, Israel R, Frisone M, et al.: Gallium nitrate for acute treatment of cancer related hypercalcemia: a randomized double blind comparison with calcitonin. Ann Intern Med 108:669–674, 1988.

    PubMed  Google Scholar 

  223. Warrell RP Jr, Murphy WK, Schulman P, O’Dwyer PJ: Gallium nitrate vs. etridronate for acute treatment of cancer related hypercalcemia randomized double blind study. J Bone Min Res 5:S271, 1990.

    Google Scholar 

  224. Yamamoto M, Takuwa Y, Masuko S, Ogata E: Effects of endogenous and exogenous parathyroid hormone on tubular reabsorption of calcium in pseudohypoparathyroidism. J Clin Endocrinol Metab 66:618–625, 1988.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Aaron Halabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roger A. L. Sutton
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Baylor College of Medicine, The Methodist Hospital, Houston, Texas, USA

    Wadi N. Suki

  2. Division of Nephrology, University of Southern California, Los Angeles, California, USA

    Shaul G. Massry

Rights and permissions

Reprints and permissions

Copyright information

© 1991 Kluwer Academic Publishers

About this chapter

Cite this chapter

Halabe, A., Sutton, R.A.L. (1991). Disorders of Calcium Metabolism. In: Suki, W.N., Massry, S.G. (eds) Therapy of Renal Diseases and Related Disorders. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-0689-4_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-0689-4_5

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-8027-9

  • Online ISBN: 978-1-4613-0689-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation